NASDAQ:HGEN - Humanigen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $27.83
  • Forecasted Upside: 68.99 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$16.47
▼ -0.02 (-0.12%)
1 month | 3 months | 12 months
Get New Humanigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HGEN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$27.83
▲ +68.99% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Humanigen in the last 3 months. The average price target is $27.83, with a high forecast of $35.00 and a low forecast of $21.00. The average price target represents a 68.99% upside from the last price of $16.47.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in Humanigen.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2021JPMorgan Chase & Co.Initiated CoverageNeutral$21.00High
i
12/23/2020National SecuritiesInitiated CoverageBuy$35.00N/A
i
12/22/2020Jefferies Financial GroupInitiated CoverageBuy$27.00Low
i
11/6/2020HC WainwrightBoost Price TargetPositive ➝ Buy$31.00 ➝ $34.00Medium
i
Rating by J. Pantginis at HC Wainwright
11/6/2020HC WainwrightReiterated RatingPositive ➝ Buy$31.00 ➝ $34.00High
i
10/21/2020Cantor FitzgeraldReiterated RatingOverweight$25.00Medium
i
Rating by L. Chen at Cantor Fitzgerald
10/20/2020Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
i
10/14/2020HC WainwrightReiterated RatingBuy$31.00High
i
Rating by J. Pantginis at HC Wainwright
10/14/2020HC WainwrightInitiated CoverageBuy$31.00High
i
10/1/2020Roth CapitalInitiated CoverageBuy$25.00High
i
9/30/2020Roth CapitalReiterated RatingBuyHigh
i
Rating by T. Butler at Roth Capital
(Data available from 3/4/2016 forward)
Humanigen logo
Humanigen, Inc., a clinical stage biopharmaceutical company, develops proprietary monoclonal antibodies for immunotherapy and oncology treatments. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes granulocyte-macrophage colony-stimulating factor, which is in Phase Ib/II clinical trial in patients with chronic myelomonocytic leukemia, and for the treatment of juvenile myelomonocytic leukemia. It also develops Ifabotuzumab, a monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005 an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic diseases. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was founded in 2000 and is based in Burlingame, California.
Read More

Today's Range

Now: $16.47
$15.83
$17.34

50 Day Range

MA: $19.61
$17.69
$23.83

52 Week Range

Now: $16.47
$1.75
$33.95

Volume

9,953 shs

Average Volume

823,020 shs

Market Capitalization

$850.13 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Humanigen?

The following equities research analysts have issued reports on Humanigen in the last twelve months: Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., National Securities, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for HGEN.

What is the current price target for Humanigen?

6 Wall Street analysts have set twelve-month price targets for Humanigen in the last year. Their average twelve-month price target is $27.83, suggesting a possible upside of 57.3%. National Securities has the highest price target set, predicting HGEN will reach $35.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $21.00 for Humanigen in the next year.
View the latest price targets for HGEN.

What is the current consensus analyst rating for Humanigen?

Humanigen currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HGEN will outperform the market and that investors should add to their positions of Humanigen.
View the latest ratings for HGEN.

What other companies compete with Humanigen?

How do I contact Humanigen's investor relations team?

Humanigen's physical mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The company's listed phone number is 650 243 3100 and its investor relations email address is [email protected] The official website for Humanigen is www.humanigen.com.